JS-019

N/A

Report date: 2024/12/25 20:00:50

Base Information

Drug NameJS-019
Drug Alias NameJS-019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsEctonucleoside triphosphate diphosphohydrolase 1 inhibitors
TargetsEctonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsSolid tumoursEosinophiliaLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Enrini Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Enrini Biotechnology Co LtdSuzhou keboruijun Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEosinophiliaLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A